These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2494737)

  • 21. Fast neutrons for BNCT.
    Wagner FM; Koester L
    Strahlenther Onkol; 1989; 165(2-3):115-7. PubMed ID: 2494712
    [No Abstract]   [Full Text] [Related]  

  • 22. The United States BNCT program.
    Robertson JS; Mahoney FJ
    Strahlenther Onkol; 1989; 165(2-3):249-51. PubMed ID: 2494742
    [No Abstract]   [Full Text] [Related]  

  • 23. A multidisciplinary program leading to a clinical trial of neutron capture therapy at Tufts-New England Medical Center and the Massachusetts Institute of Technology.
    Zamenhof RG; Madoc-Jones H; Harling OK; Bernard JA
    Strahlenther Onkol; 1989; 165(2-3):254-7. PubMed ID: 2538941
    [No Abstract]   [Full Text] [Related]  

  • 24. Distributions of sulfhydryl borane monomer and dimer in rodents and monomer in humans: boron neutron capture therapy of melanoma and glioma in boronated rodents.
    Slatkin DN; Joel DD; Fairchild RG; Micca PL; Nawrocky MM; Laster BH; Coderre JA; Finkel GC; Poletti CE; Sweet WH
    Basic Life Sci; 1989; 50():179-91. PubMed ID: 2751607
    [No Abstract]   [Full Text] [Related]  

  • 25. Boron neutron capture therapy at the crossroads: challenges and opportunities.
    Barth RF
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S3-6. PubMed ID: 19467879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computerized axial tomographic and magnetic resonance imaging scan follow-up of two patients after boron neutron capture therapy for glioblastoma multiforme.
    Marano SR; Spickard JH; Griebenow ML
    Strahlenther Onkol; 1989; 165(2-3):240-2. PubMed ID: 2538940
    [No Abstract]   [Full Text] [Related]  

  • 27. Boron chemistry and target cell affinity.
    Soloway AH; Alam F; Barth RF; Bapat BV
    Strahlenther Onkol; 1989; 165(2-3):118-20. PubMed ID: 2494713
    [No Abstract]   [Full Text] [Related]  

  • 28. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption.
    Barth RF; Yang W; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH; Soloway AH
    Cancer Res; 1997 Mar; 57(6):1129-36. PubMed ID: 9067283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated approach in the planning of neutron capture therapy.
    Ryabukhin YS
    Strahlenther Onkol; 1989; 165(2-3):158-62. PubMed ID: 2494721
    [No Abstract]   [Full Text] [Related]  

  • 30. Radiation field for BNCT experiments.
    Csom G; Zsolnay EM; Fehér S; Virágh E
    Strahlenther Onkol; 1989; 165(2-3):78-81. PubMed ID: 2494749
    [No Abstract]   [Full Text] [Related]  

  • 31. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
    Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Boronated compounds for neutron capture therapy.
    Alam F; Bapat BV; Soloway AH; Barth RF; Mafune N; Adams DM
    Strahlenther Onkol; 1989; 165(2-3):121-3. PubMed ID: 2494714
    [No Abstract]   [Full Text] [Related]  

  • 33. Boronophenylalanine for neutron capture therapy of melanoma.
    Coderre JA; Glass JD; Fairchild RG; Micca P; Kalef-Ezra J
    Strahlenther Onkol; 1989; 165(2-3):215-7. PubMed ID: 2494733
    [No Abstract]   [Full Text] [Related]  

  • 34. The incorporation of boronated substances into melanin in vitro--an experimental model for melanotic melanoma.
    Roberto A; Larsson BS
    Strahlenther Onkol; 1989; 165(2-3):165-7. PubMed ID: 2494722
    [No Abstract]   [Full Text] [Related]  

  • 35. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.
    Monti Hughes A; Heber EM; Pozzi E; Nigg DW; Calzetta O; Blaumann H; Longhino J; Nievas SI; Aromando RF; Itoiz ME; Trivillin VA; Schwint AE
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S313-7. PubMed ID: 19376711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement and analysis on neutron flux distributions in a heavy water phantom using the KUR neutron guide tube for BNCT.
    Kobayashi T; Ono M; Kanda K
    Strahlenther Onkol; 1989; 165(2-3):101-3. PubMed ID: 2494707
    [No Abstract]   [Full Text] [Related]  

  • 37. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
    Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of 10B antitumoral compounds by means of flow-injection into ESI-MS/MS.
    Basilico F; Sauerwein W; Pozzi F; Wittig A; Moss R; Mauri PL
    J Mass Spectrom; 2005 Dec; 40(12):1546-9. PubMed ID: 16320299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plan for synthesis of biomolecules for neutron capture therapy of cervical carcinoma.
    Wongwiechintana C; Choonchartprasert S; Tampitak S; Prachayasittigul S
    Strahlenther Onkol; 1989; 165(2-3):125-6. PubMed ID: 2494715
    [No Abstract]   [Full Text] [Related]  

  • 40. Biological effects of intermediate-energy neutrons and their relevance to boron neutron capture therapy.
    Mill AJ
    Strahlenther Onkol; 1989; 165(2-3):193-6. PubMed ID: 2494726
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.